Sodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate

Catalog No. :
ACOPAN962
CAS No. :
828934-41-4
Molecular Formula :
C15H18ClNaO4
Molecular Weight :
320.75

IUPAC Name:sodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate

Sodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg98%$76.00Login to see priceIn stockInquiry
50mg98%$232.00Login to see priceIn stockIn stock
100mg98%$376.00Login to see priceIn stockIn stock
250mg98%$694.00Login to see priceIn stockIn stock
1g98%$2360.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameSodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate
IUPAC Namesodium (R)-2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate
MDL No.MFCD11044452
Molecular FormulaC15H18ClNaO4
Molecular Weight320.75
SMILESO=C([C@]1(CCCCCCOC2=CC=C(Cl)C=C2)OC1)[O-].[Na+]
InChI KeyRPACBEVZENYWOL-XFULWGLBSA-M
Synonym(+)-etomoxir sodium hydrate;r(+)-2-[6-(4-chlorophenoxy)hexyl]-oxirane-2-carboxylic acid sodium salt hydrate;(+)-Etomoxir hydrate sodium salt;R(+)-2-[6-(4-Chlorophenoxy)hexyl]-oxirane-2-carboxylic acid hydrate sodium salt;Etomoxir(Nasalt);(R)-(+)-2-[6-(4-Chlorophenoxy)hexyl]-oxirane-2-carboxylic acid sodium salt;ANTI-EAPII;Etomoxir hydrate sodium
CAS No.828934-41-4
PubChem CID57345784

Synthetic Route by SureRoute

1. ACOPAN962 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACKRXT601 route compound structure diagram
    ACKRXT601124083-20-1 In Stock
  2. Then
  3. ACOPAN962 route product structure diagram
    ACOPAN962828934-41-4 In Stock
Inquiry

2. ACOPAN962 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACOPAN962 route product structure diagram
    ACOPAN962828934-41-4 In Stock
Inquiry

Comments (0)